Pentec Health (PRIVATE.PENTEC)

Overall impact
C (58)

Commentary

Pentec Health is an average overall performer. With a 'C' rating of 57.9 for overall impact (58th percentile compared to all companies), Pentec Health ranks 31st out of 46 industry peers, behind Agilent, LGC Group, Pace Analytical Services and 27 others, and ahead of Eversana, SPT Labtech, Flourish Research and 12 others. On top material causes for Pentec Health's industry (Life Sciences Tools & Services), Pentec Health performs well in Child and Maternal Health (85.3 score), Child and Maternal Health (95.2), Child and Maternal Health (85.3) and 5 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (34.9 score), Disaster Readiness and Effective Aid (34.7), Accountable Institutions (25.4) and 16 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause PRIVATE.PENTEC
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
150
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Pennsylvania, United States
Share classes
PRIVATE.PENTEC
Pentec Health
Description
Developer of compounded sterile medications and in-home specialty infusion therapies focused on patients who require access outside a hospital setting. The company offers intradialytic parenteral nutrition (IDPN) and intraperitoneal nutrition (IPN) protein therapies for malnourished dialysis patients as well as patient-specific medications that are delivered surgically implanted, programmable intrathecal pumps, thereby ensuring personalized treatments that are specific to each patient's needs.
Material causes
Ethos considers the following causes material for Pentec Health, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.